Clinical Trials | Adults with Lymphoma or Myeloma Cancer Who Will Undergo CAR T-Cell Therapy are Invited to Participate in a Research Study

The UVA Comprehensive Cancer Center is running a study for patients with Multiple Myeloma or Lymphoma (cancer). This study will enroll patients who will have CAR T-Cell Therapy as part of their regular treatment. The study uses a drug called Avatrombopag that is taken by mouth. This drug is approved by the FDA to increase platelet numbers in people with other kinds of conditions including immune thrombocytopenic purpura (ITP) and chronic liver disease. Sometimes, CAR T-Cell therapy can cause patients to have cytopenias, which means low blood cell and platelet counts. Low blood cell and platelet counts can make a person’s body have a harder time stopping bleeding if there is an injury. The goal of this study is to find out if avatrombopag helps to prevent cytopenias in patients who are at high risk for cytopenias. Participants will take this drug as told by their doctor with their regular cancer therapy. Participants will also give blood samples throughout the study. These samples will help researchers learn about how participants respond to the medication. More information can be found here: [CT>.gov link] or by contacting [email protected]. Compensation This study does not offer compensation or reimbursement.